logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer's Xarelto Approved In EU For Preventing Stroke In Patients With AF

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said Bayer HealthCare's oral anticoagulant Xarelto (rivaroxaban) has been approved by the European Commission for use in two new indications, making it the only new oral anticoagulant approved in three indications across all 27 EU member states.

Xarelto is approved for preventing stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, or AF, with one or more risk factors and for treatment of deep vein thrombosis, or DVT, and prevention of recurrent DVT and pulmonary embolism following an acute DVT in adults. It is also approved for prevention of Venous Thromboembolism, or VTE, in adult patients undergoing elective hip or knee replacement surgery.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Justice Department has initiated a probe to find out if airlines are colluding to limit seating capacity in order to benefit from higher airfares. Saudi Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud has pledged to give away his entire wealth amounting to $32 billion for charity. He said the fund will be utilized for cultural understanding, develop communities, empower women, enable youth, provide vital disaster relief and create a more tolerant and accepting world. Toyota accepted the resignation of its Chief Communications Officer Julie Hamp, following her arrest in Japan for allegedly mailing banned painkillers to her address in Japan from U.S.
comments powered by Disqus
Follow RTT